Diana Röttger joins LifeArc Ventures as Investment Principal as portfolio grows
LONDON, UK, 17 June 2025 — LifeArc Ventures, which invests in innovative early-stage life science companies as part of LifeArc, today announced the appointment of Diana Röttger as Investment Principal.
Clare Terlouw, Head of LifeArc Ventures, said: “We are delighted to welcome Diana to the LifeArc Ventures team. Her background and track record of investing in tech powered life sciences companies will bring an additional perspective as we support and grow our portfolio. We have had a remarkably busy start to 2025 with two new investments expanding our international reach, and we look forward to building on this momentum.”
Diana Röttger, added: “It’s exciting to be part of a team and a wider organisation committed to backing science that truly changes lives. With a background in medical computer science, I’ve always been drawn to transformative innovation at the intersection of data, engineering, and human health. LifeArc’s mission to fund and support transformational science aligns perfectly with my passion to support companies with the potential to make a real-world impact.”
Before joining LifeArc Ventures, London-based Diana was a Principal at Apex Ventures, a European deeptech VC investor. There, she focused on early-stage investments through their medical fund, specializing in opportunities at the intersection of technology, biology, and healthcare. Diana was responsible for the sourcing, evaluation, financing and support of health and bio startups in Europe. She held six portfolio board positions through this role, providing supervision, guidance and support to CardiaTec – an AI based Cardiovascular disease therapeutics company; Mindpeak – an AI based tissue diagnostics firm and Quibim – a quantitative biomarkers, companion diagnostics and imaging tools company, as well as Novoic, Robeauté and Senisca.
Prior to Apex Ventures, Diana worked as the Chief Scientific Alliance Officer for IAG (Image Analysis Group), a software scale-up specialising in AI imaging technology for biopharma, where she founded, managed and grew their oncology business. Diana was a Research Observer at Harvard Medical School in Cambridge, MA focused on software for medical diagnosis and surgical planning. She has a Ph.D from the University of Koblenz-Landau in Germany on reconstruction and visualisation of neuronal pathways with application in neuroscience and a MSc. in medical computer science.
Notes to Editors
LifeArc is a not-for-profit medical research organisation that turns promising scientific research into impact for people living with rare diseases and Global Health infections. We have been doing this for more than 30 years and our work has resulted in five licensed medicines, including cancer drug, pembrolizumab, and lecanemab for Alzheimer’s disease. Our model is built on collaboration, and through our LifeArc Ventures team, we invest in innovative life sciences companies with significant follow-on investment reserved for successful portfolio companies. Our ventures approach focuses on investing in novel translational science and technology with a dual goal of generating financial returns to the charity and positive impact for patients.
Find out more on www.lifearc.org / https://lifearcventures.com or follow us on LinkedIn or Twitter (@LifeArcVentures).
